Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CARBAMAZEPINE

All products: general benefit

Other products in the same Health Canada class (N03A, N03AF) — coverage varies; not interchangeable

  • Eslicarbazepine (Aptiom): limited Use 430
  • Oxcarbazepine (Trileptal): not a benefit
  • Rufinamide (Banzel): not a benefit
  • Clonazepam (Rivotril): general benefit
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit

14 more in the class list below

Taro-Carbamazepine · DIN 02244404 · 200mg · chewable tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Carbamazepine · DIN 02244404 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2003-04-16 Health Canada: Marketed since 2002-04-19 · brand TARO-CARBAMAZEPINE CHEWABLE TABLETS · ATC N03AF01 CARBAMAZEPINE · form Tablet (chewable) · route Oral · ingredients CARBAMAZEPINE 200 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Carbamazepine: Formulary list price $0.3302/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3302 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68373 · Verify on the e-Formulary ↗ (DIN 02244404)

Source record
DIN 02244404: Taro-Carbamazepine Raw flags: sec3=Y Item: 281200050; group id 421; item number 1042; lccId None; manufacturer id TAR Source form: Chew Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3302; ministry $0.3302 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68373
Interchangeable products
Tegretol · DIN 00665088 · not recorded
Shortage status: resolved shortage (ended 2020-03-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244404
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

ESLICARBAZEPINE ACETATE

· 12 products · Limited Use, codes 430 · strengths: 200mg, 400mg, 600mg, 800mg · Tab

OXCARBAZEPINE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 150mg, 300mg, 600mg · Tab

RUFINAMIDE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 200mg, 400mg · Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Epilepsy: Adults (> 18 years of age) TEGRETOL® (carbamazepine) is indicated for use as an anticonvulsant drug either alone or in combination with other anticonvulsant drugs. Carbamazepine is not effective in controlling absence, myoclonic or atonic seizures, and does not prevent the generalization of epileptic discharge. Moreover, exacerbation of seizures may occasionally occur in patients with atypical absences. Trigeminal Neuralgia: Adults (> 18 years of age) TEGRETOL is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). It should not be used preventively during periods of remission. In some patients, TEGRETOL has relieved glossopharyngeal neuralgia. For patients who fail to respond to TEGRETOL, or who are sensitive to the drug, recourse to other accepted measures must be considered. Carbamazepine is not a simple analgesic and should not be used to relieve trivial facial pains or headaches. Treatment of Acute Mania and Prophylaxis in Bipolar (Manic-Depressive) Disorders: Adults (> 18 years of age) TEGRETOL may be used… https://pdf.hres.ca/dpd_pm/00085662.PDF PM date: 2026-07-31 Source product: TEGRETOL; DIN 00010405; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.